XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
The companies will work with investigators to share the results with the scientific community
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
